HOXA9甲基化DNA作为卵巢恶性肿瘤的诊断生物标志物。
HOXA9-methylated DNA as a diagnostic biomarker of ovarian malignancy.
作者信息
Faaborg Louise, Jakobsen Anders, Waldstrøm Marianne, Petersen Christina B, Andersen Rikke F, Steffensen Karina D
机构信息
Department of Oncology, Lillebaelt Hospital, University Hospital of Southern Denmark, Vejle, 7100, Denmark.
Institute of Regional Health Research, University of Southern Denmark, Odense, 5000, Denmark.
出版信息
Biomark Med. 2021 Oct;15(15):1309-1317. doi: 10.2217/bmm-2021-0144. Epub 2021 Sep 13.
In ovarian cancer, methylated HOXA9 (meth-HOXA9) has been proposed as a relevant biomarker, however, its role in the carcinogenic development remains unknown. This study aimed at evaluating meth-HOXA9 as a diagnostic biomarker in ovarian cancer. The meth-HOXA9 status was examined in 138 tissue specimens encompassing normal ovaries, benign- and borderline tumors, and ovarian cancer using droplet digital PCR. Meth-HOXA9 was detected in 93% (82/88) and 88% (14/16) of ovarian cancer and borderline tumors, respectively. In patients with benign ovarian tumors meth-HOXA9 was detected in 17% (3/18). Using receiver operating characteristic (ROC) analysis meth-HOXA9 had a diagnostic accuracy of 98%. Meth-HOXA9 is highly cancer specific and could serve as a general diagnostic marker of ovarian malignancy.
在卵巢癌中，甲基化的HOXA9（meth-HOXA9）被认为是一种相关生物标志物，然而，其在致癌发展中的作用仍不清楚。本研究旨在评估meth-HOXA9作为卵巢癌诊断生物标志物的价值。使用液滴数字PCR检测了138份组织标本中的meth-HOXA9状态，这些标本包括正常卵巢、良性和交界性肿瘤以及卵巢癌。meth-HOXA9分别在93%（82/88）的卵巢癌和88%（14/16）的交界性肿瘤中被检测到。在良性卵巢肿瘤患者中，17%（3/18）检测到meth-HOXA9。使用受试者工作特征（ROC）分析，meth-HOXA9的诊断准确率为98%。meth-HOXA9具有高度的癌症特异性，可作为卵巢恶性肿瘤的通用诊断标志物。
Zotero 插件